(article 14, subparagraph 1 of the law of 2 May 2007 regarding the disclosure of important shareholdings in listed companies)
Regulatory News:
ASIT biotech (Paris:ASIT) (BSE:ASIT) (ASIT BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces that it has received a transparency notification dated 24 September, 2018, the result of which is following a capital increase completed on September 6th that SA S.R.I.B. and SA Brustart have now jointly 4,92% of the Company's voting rights, and has thus decreased their stake below the 5% threshold.
The statement dated 24 September, 2018 notably includes the following information:
- Purpose of the notification
Passive crossing of a threshold
- Notification by
A parent undertaking or a controlling person
- Person subject to the notification requirement
S.R.I.B. SA Rue Stassart 32, 1050 Bruxelles
Brustart SA Rue Stassart 32, 1050 Bruxelles
- Date of the transaction
September 6th, 2018
- Threshold crossed (%)
Downward crossing of the 5% threshold
- Denominator
A total of 17,506,777 voting rights
- This notification is available on ASIT biotech's website, in the Documentation Regulated information section:
https://www.asitbiotech.com/investors/documentation
About ASIT biotech
ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech's product pipeline contains three novel ASIT+ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+ and house dust mite: hdm-ASIT+), and food allergies (peanut allergy: pnt-ASIT+) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+ platform is flexible and would be applicable across a range of allergies.
ASIT biotech has a headcount of 26 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.
Further information can be found at www.asitbiotech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180928005343/en/
Contacts:
Company
ASIT biotech
Thierry Legon, CEO
Tel.: +32 2 264 03 90
investors@asitbiotech.com
or
Media and Investor Relations France
NewCap
Dusan Oresansky Pierre Laurent
Tel.: +33 1 44 71 94 92
asitbiotech@newcap.eu
or
Media Relations Belgium
Laure-Eve Monfort
Tel.: +32 2 290 90 93
monfort@comfi.be